Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBohra, Anuj-
dc.contributor.authorWorland, Thomas-
dc.contributor.authorHui, Samuel-
dc.contributor.authorTerbah, Ryma-
dc.contributor.authorFarrell, Ann-
dc.contributor.authorRobertson, Marcus-
dc.identifier.citationWorld Journal of Gastroenterology 2020; 26(18): 2221-2231en_US
dc.description.abstractHepatic encephalopathy (HE) is a reversible neuropsychiatric complication of liver cirrhosis and occurs in up to 50% of cirrhotic patients. Studies examining the prognostic significance of HE are limited despite the high prevalence in cirrhosis. To define the clinical outcomes of patients after an episode of HE treated with current standards-of-care. All patients hospitalised with HE requiring Rifaximin to 3 tertiary centres over 46-mo (2012-2016) were identified via pharmacy dispensing records. Patients with hepatocellular carcinoma and those prescribed Rifaximin prior to admission were excluded. Medical records were reviewed to determine baseline characteristics and survival. The Kaplan-Meier method was used to calculate survival probability. Univariate survival analysis was performed with variables reaching statistical significance included in a multivariate analysis. The primary outcome was 12-mo mortality following commencement of Rifaximin. 188 patients were included. Median age was 57 years (IQR 50-65), 71% were male and median model for end stage liver disease and Child Pugh scores were 25 (IQR 18-31) and 11 (IQR 9-12) respectively. The most common causes of cirrhosis were alcohol (62%), hepatitis C (31%) and non-alcoholic fatty liver disease (20%). A precipitating cause for HE was found in 92% patients with infection (43%), GI bleeding (16%), medication non-compliance (15%) and electrolyte imbalance (14%) the most common. During a mean follow up period of 12 ± 13 mo 107 (57%) patients died and 32 (17%) received orthotopic liver transplantation. The most common causes of death were decompensated chronic liver disease (57%) and sepsis (19%). The probability of survival was 44% and 35% at 12- and 24-mo respectively. At multivariate analysis a model for end stage liver disease > 15 and international normalised ratio reached statistical significance in predicting mortality. Despite advances made in the management of HE patients continue to have poor survival. Thus, in all patients presenting with HE the appropriateness of orthotopic liver transplantation should be considered.en_US
dc.subjectHepatic encephalopathyen_US
dc.subjectPortal hypertensionen_US
dc.titlePrognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleWorld Journal of Gastroenterologyen_US
dc.identifier.affiliationDepartment of Gastroenterology, Monash Health, Clayton 3168, Victoria, Australiaen_US
dc.identifier.affiliationGastroenterology and Hepatologyen_US
dc.type.austinJournal Article-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristype and Hepatology- and Hepatology- Liver Transplant Unit- (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 9, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.